ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

This is a clinical milestone, but real investor value is years away and unproven.

What the company is saying

ADC Therapeutics is telling investors that it has completed enrollment in the LOTIS-7 Phase 1b trial, testing ZYNLONTA in combination with glofitamab for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The company highlights that 100 patients have been enrolled at the selected 150 µg/kg dose, with 70% from the US and 30% from the EU, and a median patient age of 66. They emphasize previously reported data showing an 89.8% overall response rate and 77.6% complete response rate in a subset of 49 patients with at least six months of follow-up, framing these as strong efficacy signals. The announcement is careful to stress the study’s primary endpoints (safety and tolerability) and a broad set of secondary endpoints, but does not provide new results for these. Management’s tone is upbeat and forward-looking, projecting confidence in the combination’s potential and in their ability to move toward regulatory and publication milestones. The company states it will share full data at a medical meeting and submit for publication by the end of 2026, but does not commit to any regulatory submission or commercial launch timeline. Notable individuals mentioned include Mohamed Zaki, MD, PhD, Chief Medical Officer, whose involvement signals clinical leadership but does not alter the risk profile for investors. The narrative fits a classic biotech playbook: highlight operational progress, reference promising early data, and set expectations for future milestones without overcommitting. Compared to prior communications (which are not available for review), there is no evidence of a shift in messaging, but the focus remains on clinical progress rather than commercial or financial performance.

What the data suggests

The disclosed numbers confirm that 100 patients have been enrolled in the LOTIS-7 trial at the 150 µg/kg dose, with a clear breakdown of patient demographics: 46% relapsed, 54% primary refractory, median age 66, and a median of three prior lines of therapy. The only efficacy data provided is from a previously reported interim analysis of 49 efficacy-evaluable patients, showing an 89.8% overall response rate and 77.6% complete response rate after at least six months of follow-up. There is no new data on safety, tolerability, or secondary endpoints such as duration of response, progression-free survival, or overall survival. No financial data—such as revenue, expenses, cash position, or burn rate—is disclosed, making it impossible to assess the company’s financial health or trajectory. The gap between the company’s positive framing and the actual evidence is significant: the main achievement is enrollment completion, not new clinical or commercial validation. Prior targets for enrollment have been met, but there is no information on whether previous efficacy or safety targets have been achieved in the full cohort. The quality of clinical disclosure is high for operational details but incomplete for efficacy and safety outcomes, and entirely lacking for financials. An independent analyst would conclude that while the operational milestone is real, the investment case remains speculative until full data is released and regulatory or commercial progress is demonstrated.

Analysis

The announcement's tone is positive, focusing on the completion of clinical trial enrollment and previously reported efficacy data. The main realised milestone is the completion of enrollment for the LOTIS-7 Phase 1b trial, which is a genuine operational achievement. However, most of the forward-looking claims—such as plans to share full data by the end of 2026 and to assess regulatory pathways—are aspirational and will not materialise for at least two years. The only efficacy data cited is from a subset of 49 patients, not the full cohort, and no new clinical or financial results are disclosed. There is no mention of new capital outlay or immediate commercial impact, and the announcement lacks financial performance data. The gap between narrative and evidence is moderate: while the enrollment milestone is real, the positive framing around future data and regulatory plans is not yet substantiated by new results.

Risk flags

• ●The majority of the company’s claims are forward-looking, with full data and any regulatory action not expected until late 2026 or beyond. This means investors face a long wait with no guarantee of positive outcomes.
• ●There is no new efficacy or safety data for the full 100-patient cohort; all efficacy claims are based on a subset of 49 patients, which may not be representative. This raises the risk that final results could disappoint.
• ●No financial data is disclosed—no revenue, cash position, or burn rate—leaving investors blind to the company’s financial health and capital needs. This is a major red flag for any capital-intensive biotech.
• ●The announcement lacks any mention of commercial partnerships, regulatory submissions, or near-term monetization, suggesting that even if clinical results are positive, revenue generation is distant and uncertain.
• ●Operational risk is present: the trial’s primary endpoints are safety and tolerability, but no new safety data is provided. If adverse events emerge in the full cohort, the program could be delayed or derailed.
• ●Disclosure quality is uneven: while operational details are thorough, key clinical and all financial metrics are missing. This selective transparency is a pattern that should concern investors.
• ●Timeline risk is high: with data not expected until the end of 2026, any delays or negative results could significantly impact the stock before investors have a chance to react to new information.
• ●Geographic execution risk exists, as the trial spans 30 sites across the US and EU, which can introduce variability in patient management and data quality, potentially complicating regulatory review.

Bottom line

For investors, this announcement is a classic early-stage biotech update: the company has hit an operational milestone by completing enrollment in a key trial, but there is no new clinical or financial data to support a change in valuation. The narrative is credible in terms of operational progress, but the investment case is entirely unproven until full efficacy and safety data are released—likely not before late 2026. No notable institutional investors or partners are mentioned, so there is no external validation or de-risking of the program. To change this assessment, the company would need to disclose comprehensive, full-cohort efficacy and safety results, or announce a binding regulatory or commercial milestone. Investors should watch for the next major catalyst: the release of full LOTIS-7 data, any regulatory submission, or a partnership announcement. Until then, this is a signal to monitor, not to act on—there is no basis for a near-term investment decision based on this update alone. The most important takeaway is that while operational progress is real, the path to value realization is long, risky, and entirely dependent on future data that is years away.

Announcement summary

(NYSE: ADCT) ADC Therapeutics SA announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with glofitamab in 100 relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) patients at the selected 150 µg/kg dose. Enrollment occurred in 30 total sites with 70% of patients in the US and 30% in the EU, and the median age of patients was 66 years. The study included 46% relapsed and 54% primary refractory patients, with a median of three prior lines of therapy. Previously reported data from the study demonstrated an 89.8% overall response rate (ORR) and 77.6% complete response (CR) across 49 efficacy-evaluable patients with a minimum of 6 months of follow-up. Primary endpoints include safety and tolerability, while secondary endpoints include overall response rate, duration of response, complete response, relapse free survival, progression-free survival, overall survival, pharmacokinetics, and immunogenicity. The company plans to share full data from LOTIS-7 at a medical meeting and submit the results for publication by the end of 2026. ADC Therapeutics is headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, United States.

Disagree with this article?